Photo: streetinsider.com
Annovis reports biomarker data showing inflammation reduction with buntanetap
Annovis Bio Inc. reported promising biomarker data showing that its drug candidate buntanetap significantly reduces inflammation and improves neuronal health in Alzheimers disease patients.
- In a Phase 2/3 study, Annovis Bio Inc. found that buntanetap led to a notable reduction in inflammatory markers associated with Alzheimers disease, indicating potential therapeutic benefits.
- The analysis highlighted an attenuation of levels of acute-phase protein and inflammatory cytokines, including Interferon gamma and Interleukin 5, which are linked to neurodegenerative disease.
- Buntanetaps effects were evident through improved neuron health indicators, emphasizing its role in addressing inflammation and promoting neuronal resilience in Alzheimers disease patients.
Why It Matters
This breakthrough suggests that buntanetap may offer a new avenue for treating Alzheimers disease by targeting inflammation, a key factor in neurodegenerative disease progression, and improving patient outcomes. Recognizing the importance of biomarkers in treatment efficacy could reshape future Alzheimers research and therapeutic strategies.